Renatus has been granted a patent for novel cyclodextrins for the treatment of cholesterol-associated diseases by Korea Intellectual Property Office (KIPO).

ATP-binding cassette transporter A1 (ABCA1) is a transmembrane protein ubiquitously expressed in human tissue and plays a crucial role in cellular cholesterol homeostasis.

Downregulation of ABCA1 protein and compromised cholesterol efflux can be observed in various diseases including atherosclerosis, chronic kidney disease, Alzheimer’s disease, Niemann-Pick Type C, etc.

Hydroxypropyl-beta-cyclodextrin (HPβCD) promotes expression of ABCA1 and ABCA1-mediated cholesterol efflux and is in clinical trials for Niemann-Pick Type C, Alzheimer’s disease, and focal segmental glomerulosclerosis.

Compared to HPβCD, RENATUS's proprioetary and novel cyclodextrin RN-005 exhibits superior improvements in cholesterol efflux, expression of ABCA1, and formation of cholesterol ester in diseased macrophages fed with excessive free cholesterol. In addition, RN-005 exhibits less cytotoxicity and hemolytic activity at high concentrations, implying its greater safety.

About RENATUS

Renatus is a pharma company thriving to develop next generation cyclodextrins to provide safe treatment options for patients living with cholesterol-associated diseases. Renatus seeks to provide critical impact in developing translational cyclodextrin therapies and fulfill its vision to protect the world from various cholesterol-associate diseases. For more information, please visit www.renatustx.com